Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - venlafaxine hydrochloride - oral tablet - 37.5mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - venlafaxine hydrochloride - oral tablet - 75mg

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dexcel pharma gmbh (8000867) - irbesartan - filmtablette - teil 1 - filmtablette; irbesartan (27633) 300 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dexcel pharma gmbh (8000867) - irbesartan - filmtablette - teil 1 - filmtablette; irbesartan (27633) 150 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dexcel pharma gmbh (8000867) - irbesartan - filmtablette - teil 1 - filmtablette; irbesartan (27633) 75 milligramm

Israel - arabisk - Ministry of Health

dexcel pharma technologies ltd - losartan potassium 50 mg - tablets - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

Israel - russisk - Ministry of Health

dexcel pharma technologies ltd - losartan potassium 50 mg - tablets - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

Israel - hebraisk - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate - טבליות מצופות פילם - clopidogrel as besylate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi

Israel - hebraisk - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 12.5 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii) , when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended.

Israel - hebraisk - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric